This award recognises the most innovative products on the market. Eligible products must have been launched into the UK market after 1 January 2017. The judges will look for genuine innovation or product advancement leading to treatment for new indications, quicker or easier treatments, better treatment outcomes, enhanced patient safety, backed up by sound evidence. There will be no voting process and the winner will be decided by the judging panel. Please note that the word count for each question is inclusive of references.
This entry is based on skinbetter science’s™ AlphaRet® Overnight Cream, one of the most powerful retinoids to enter the skin rejuvenation market since tretinoin offering optimal efficacy with minimal irritation. The formulation encompasses a unique combination of a retinoid and an AHA that provides visible skin rejuvenation with little- to-no irritation. AHAs and retinoids are two gold standard ingredients that are an ideal combination for skin rejuvenation that, historically, have not been successfully combined in one stable formula – until now.
Developed by Jonah Shacknai, Executive Chairman of skinbetter science, and a leading team of dermatology industry experts, this cutting-edge, data-driven science is the principal driving force behind all the unique formulations and the skinbetter science team of aesthetic experts have a profound understanding of skin ageing and what it takes to help defy the effects of time.
Tapping into a rich dermatological heritage, the team at skinbetter science set out to create a new paradigm in clinical skincare, developing breakthrough technology from all corners of the world to deliver the highest standards of clinical efficacy and product tolerability, thereby inspiring the highest levels of trust from practitioners and consumers alike. The skinbetter science’s range of products are designed to uncomplicated to use in clinic.
AestheticSource took on this clinically proven brand due to its heritage of innovation, excellent marketing and product effectiveness. We had a soft launch at ACE in April 2018 and then a full launch at FACE with a two-hour workshop with skinbetter’s Chris Kraneiss as well as branded reception, Lifts and Floors. We have exclusive regional meetings taking place in Q4 for each region.
The Novoxel Tixel system was developed to produce dramatic results comparable to those achieved with fractional ablative lasers like CO2, but with significant benefits over competitive technologies both for the patients and the users. Tixel was launched by AZTEC Services in UK with a workshop presented by Dr Harryono Judodihardjo at the Olympia Hilton during the Aesthetic Medicine Conference, in January 2017. This workshop was also attended by Raphi Shavit, founder member of Novoxel in Israel. Later on in October 2017 the Mezotix system was launched in UK by AZTEC Services at CCR Expo, where we had a live treatment demonstration and presentation by Consultant Dermatologist Dr Sajjad Rajpar FRCP. Mezotix uses the same TMA technology as Tixel but is slightly smaller and has different treatment parameters to Tixel. Having Tixel and Mezotix now enables us to offer these amazing systems to doctors, nurses, and aesthetic therapists as the treatment parameters can be set at an appropriate level for the different qualifications of users.
SkinPen Precision was Launched in the UK in January 2017.
Mechanical Microneedling is the mechanical process of using tiny needles to create thousands of “micro” channels in the skin to stimulate the wound healing response mechanism and remodelling of collagen process. Though it’s been safely used by medical professionals for a wide variety of skin conditions since the 1990s, mechanical microneedling has suffered from little oversight in the industry and was in urgent need of redesign for the correct classification and for patient safety against Cross contamination.
In March 2018, after three years of proactive work with the FDA designed to clean up the microneedling arena, Bellus Medical – the manufacturer of Skinpen Precision based in Dallas Texas - earned the first and only FDA clearance of a microneedling device with its flagship product, SkinPen Precision®. The clearance established a new microneedling classification and category, making SkinPen the only legally marketed Class 2 microneedling pen in the USA setting a new standard.
The following three contamination path shields for mechanical needling for patient safety have been addressed:
First is the cartridge 100% double lined sealed providing ‘ingress protection’ (the Measurement of fluids that can enter an electrical component).
Second is the pen 100% ultrasonically sealed, necessary because it’s virtually impossible to clean the inside of a pen.
The Third is a protective sheath covering for handling, to protect the pen from blood contamination by the operator.
More fundamentally, SkinPen qualifies as “biocompatible” because none of its components pose an unacceptable risk of a potential adverse biological response. Similarly, the device is compliant with the Restriction of Hazardous Substances (RoHS), a European Union rule that restricts the use of hazardous materials in electrical and electronic products.
Celluma was developed to offer a convenient solution in an affordable, all-in-one system to address the challenges of an aesthetic practice. The award winning and patented Celluma uses clinically proven wavelengths of light energy to improve cellular health by accelerating the repair and replenishment of compromised tissue cells. While similar devices on the market claim to do the same, they often require multiple panels, head attachments or additional accessories in order to treat specific conditions or accommodate different parts of the body.
Manufactured by BioPhotas, Inc. in Anaheim, California, Celluma was launched at the 2018 FACE Conference following an overwhelming response at the 2017 CCR Conference in London. This product already has an established base of Practitioners in the UK following its approval as a Class IIA Medical Device in 2016.
Derma-Seal™ is a novel and unique polymer sealant that may be sprayed on the skin or applied on specific areas which have been punctured by a needle or cannula entry site. It was developed in response to the difficulties that aesthetic practitioners have with patient compliance following non-surgical cosmetic injections. Patients are advised not to apply make-up, or touch the areas that have been injected in order to reduce risks of infection. Derma-Seal™ once applied to the area dries quickly and allows the patient to apply make-up immediately and forms a physical barrier to environmental contaminants . The risk of injection site infection and the introduction of infective agents that may cause a delayed infection is potentially reduced with this unique antiseptic and sealant spray.
Derma-Seal™ had a “soft launch” in the UK market in April 2018. Initial demonstrations on its clinical use was performed at expert peer-to-peer conferences and press releases followed on from this. Small groups of practitioners were introduced to the use of Derma-Seal™ in clinical teaching to introduce this product into clinical use. Discussions are ongoing with leading distributors in the UK and internationally who are considering taking on Derma-seal™ into their portfolio.
PRX-T33 is a revolutionary non-injectable topical dermal bio revitalisation treatment effecting a powerful dermal stimulation through a non-invasive and pain-free in-clinic procedure. The clinical development of this product took 10 years, and an International patent has been granted for the protection of its innovation. The treatment is complemented by a home care range, specifically formulated to enhance and prolong its effects. Together, they form an intensive rejuvenation programme.
PRX-T33 was launched in the UK in March 2017 and stemmed from a dermatologist’s desire to offer a revolutionary new approach in the field of tissue regeneration: intense dermal stimulation without invasiveness. Invasive treatments entail interruption of social life and risks for the patients.
PRX-T33 is a Class I medical device with a patented formula that regulates hydrogen peroxide (H2O2) and trichloroacetic acid (TCA) in active concentrations. The PRX-T33 formula combination quickly penetrates the dermis, activating a process of regeneration without attacking the epidermis . Promoting stimulation of fibroblasts and growth factors without causing inflammation or damaging the skin, PRX-T33 is suitable for all skin types, treats skin elastosis on the face and cleavage, prevents atrophic scarring, treats melasma and post inflammatory hyperpigmentation.
“PRX-T33 is a great product for me to use in my clinic. Less downtime for my clients in comparison to other products with fantastic results. It’s a quick and easy procedure to perform leaving the clients with refreshed skin. Especially good results I have noticed for acne scars.” Dr Joe Stolte – MedFacials
There are multiple factors that influence the development of cellulite dimples, including hormones, genetics, a sedentary or stressful lifestyle, and diet or weight gain. (2) However, what many people are unaware of is that the structural cause of cellulite is anatomical and a result of tethered fibrous septae bands (these bands connect the skin to underlying tissue at select points). (1)
M-CEL-UKI-0251 Date of Preparation July 2018
The BYONIK® Pulse-Triggered Laser which is guided by your pulse forges a new path in anti-ageing and skin health. The patented method allows non-invasive, pain free, non-surgical bio lifting with the aim of visibly reducing the signs of skin-ageing. Working at a cellular level and via light induced transmembrane convection, with its 3 phase hyaluronic acid gels embedded with antioxidants, which repairs skin and locks in hydration.
The BYONIK® laser combines two wavelengths 658nm and 806nm, for a non-invasive and non-ablative treatment to the skin. The pulse-triggered-laser adjusts its frequency to each individual patient’s pulse during the entire treatment allowing maximal antioxidant absorption into the skin cells. With this laser technology working at a cellular level, cell metabolism is stimulated, telomeres are protected, and cellular function is improved. Visible signs of ageing can be reversed by this cellular rejuvenation process with this pain free treatment method, so that the skin becomes more youthful.
BYONIK® Pulse Triggered Laser‘s concept was created by beauty lumis GmbH in cooperation with the scientists of the Ulm University over 10 years ago and is the FIRST and ONLY Pulse Triggered Laser in the world. Developed to bring innovation, safety and efficacy to patients to set a new standard for non-ablative laser skin rejuvenation.
The BYONIK® was launched in the UK at the ACE Exhibition in London, April 2018 and Pure Swiss Aesthetics Ltd were appointed in June 2018 as the exclusive distributors for the UK and sales partners in Ireland.
Combining pain relieving and disinfection properties, for use both pre- and post-cosmetic injection, the mask is a first-of-its-kind innovation to deliver multiple benefits to patients in a single-use cellulose mask.
The drive behind TSK Laboratories is in the innovation of needle technologies, with the ethos of ‘injections made perfect’. It is this desire to make the whole injection process, from start to finish, as comfortable, efficient and effective as possible which saw them look to those areas where their current portfolio did not extend, namely the pre- and post-injection experience. Development of the TSK Anti-microbial Ice Mask™ takes the quality of the injection process closer to perfection.
The product uses a specially patented formula which combines Swiss technology for facial cooling with an anti-microbial. It can be applied to the skin as a sanitiser and numbing agent, also helping to reduce the risk of infection and post-injection side effects including bruising, swelling and redness. Vitamin-rich moisturisers have anti-ageing benefits and the deeper cooling effect tightens facial ligaments resulting in the reduced appearance of fine lines. The psychological benefits derived from the pre-treatment application of the mask should also not be overlooked. It serves to calm and distract the patient, mitigating pre-treatment anxiety.
Other products claim to deliver some of these benefits, but never has this combination been achieved in a single, innovative device.
